A major goal of Texas Biologics is to strengthen and expand biomedical translational research at UT Austin. One mechanism to achieve this goal is to provide financial support for projects in biologics discovery and development. We launched the TXBio Pilot Grant Program to foster research across campus.
Current Funding Opportunities
The TXBio Pilot Grant Program is now CLOSED.
We anticipate holding yearly or bi-yearly grant programs. More opportunities will be posted here as available.
For additional funding opportunities, or to leverage your TXBio Pilot Grant funding, see UT's Internal Funding Opportunities.
2024 Pilot Grant Awardees
Development of bifunctional peptide-antibiotic conjugates for the treatment of the pan-resistant pathogen Stenotrophomonas maltophilia
- Despoina Mavridou, Ph.D., College of Natural Sciences
- Kevin Dalby, Ph.D., College of Pharmacy
- Jennifer Maynard, Ph.D., Cockrell School of Engineering (consulting role)
Development and Mechanistic Studies of an Inosine-Degrading Enzyme for Breast Cancer Therapy
- Everett Stone, Ph.D., College of Natural Sciences
Connexin-based biologics for restoration of synchronous beating following myocardial infarction
- Janeta Zoldan, Ph.D., Cockrell School of Engineering
- Jeanne Stachowiak, Ph.D., Cockrell School of Engineering
- Zhengrong Cui, Ph.D., College of Pharmacy
Smart EnteroPatho Nanoparticles for the Paracellular Delivery of Orally Administered Biologics
- Brian Belardi, Ph.D., Cockrell School of Engineering
- Nicholas Peppas, Ph.D., Cockrell School of Engineering
2023 Pilot Grant Awardees
Targeted in situ production of a HER2-specific nanobody for breast cancer
- Jaquelin Dudley, Ph.D., College of Natural Sciences
- Jennifer Maynard, Ph.D., Cockrell School of Engineering (consulting role)
Engineering RNA polymerases for efficiently producing mRNA vaccines
- Andrew Ellington, Ph.D., College of Natural Sciences
2022 Pilot Grant Awardees
Engineered Proteoliposome Therapeutics for Glycocalyx Enhancement in Disease
- Aaron Baker, Ph.D., Cockrell School of Engineering
- Linda J. Noble-Haeusslein, Ph.D., Dell Medical School, College of Liberal Arts
Eliminating Pancreatic Cancer Stem Cells with a Bispecific Antibody Binding a2b1 Integrin
- William Matsui, M.D., Dell Medical School
- Jennifer Maynard, Ph.D., Cockrell School of Engineering (consulting role)
Developing a Bifunctional Anti-biofilm Biologic Agent
- Walter L. Fast, Ph.D., College of Pharmacy
- Hugh D. Smyth, Ph.D., College of Pharmacy
Developing Adaptable, Extracellular Drug Reservoirs for Treating Glioblastoma
- Benjamin Umlauf, Ph.D., Dell Medical School
